Ligand Pharmaceuticals (LGND) Goodwill & Intangibles (2010 - 2026)

Ligand Pharmaceuticals has disclosed Goodwill & Intangibles across 17 years of filings, most recently posting $318.9 million for Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $318.9 million, down 11.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $318.9 million (down 11.4% YoY), and the FY2025 annual result was $327.0 million, down 12.08% from the prior year.
• Goodwill & Intangibles came in at $318.9 million for Q1 2026 at Ligand Pharmaceuticals, down from $327.0 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $709.6 million in Q2 2022 to a low of $303.3 million in Q4 2023.
• The 5-year median for Goodwill & Intangibles is $371.9 million (2024), against an average of $408.0 million.
• Across the five-year window, Goodwill & Intangibles sank 39.25% in 2023 and gained 22.61% in 2024, its largest moves.
• Ligand Pharmaceuticals' Goodwill & Intangibles stood at $342.5 million in 2022, then retreated by 11.43% to $303.3 million in 2023, then climbed by 22.61% to $371.9 million in 2024, then declined by 12.08% to $327.0 million in 2025, then decreased by 2.48% to $318.9 million in 2026.
• The last three Goodwill & Intangibles figures came in at $318.9 million (Q1 2026), $327.0 million (Q4 2025), and $335.1 million (Q3 2025), per Business Quant data.